These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 400731)

  • 21. Low dietary sodium and exogenous angiotensin II infusion decrease plasma adiponectin concentrations in healthy men.
    Lely AT; Krikken JA; Bakker SJ; Boomsma F; Dullaart RP; Wolffenbuttel BH; Navis G
    J Clin Endocrinol Metab; 2007 May; 92(5):1821-6. PubMed ID: 17341566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone.
    Carey RM; Thorner MO; Ortt EM
    J Clin Invest; 1979 Apr; 63(4):727-35. PubMed ID: 438333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration.
    Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
    Prog Biochem Pharmacol; 1976; 12():230-41. PubMed ID: 1019166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abnormal adrenal responsiveness and angiotensin II dependency in high renin essential hypertension.
    Dluhy RG; Bavli SZ; Leung FK; Solomon HS; Moore TJ; Hollenberg NK; Williams GH
    J Clin Invest; 1979 Nov; 64(5):1270-6. PubMed ID: 500810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rate of activation of renin-angiotensin-aldosterone axis and sodium intake in rats.
    Holtzman E; Braley LM; Menachery A; Williams GH; Hollenberg NK
    Am J Physiol; 1989 May; 256(5 Pt 2):H1311-5. PubMed ID: 2655479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopaminergic blockade of the renin-angiotensin-aldosterone system: effect of high and low sodium intakes.
    Gordon MB; Moore TJ; Dluhy RG; Williams GH
    Clin Endocrinol (Oxf); 1983 Oct; 19(4):415-25. PubMed ID: 6354522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium space and intravascular volume: dietary sodium effects in cystic fibrosis and healthy adolescent subjects.
    Legris GJ; Dearborn D; Stern RC; Geiss CL; Hopfer U; Douglas JG; Doershuk CF
    Pediatrics; 1998 Jan; 101(1 Pt 1):48-56. PubMed ID: 9417150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of the angiotensin II antagonist saralasin on plasma aldosterone concentration and on blood pressure before and during sodium depletion in normal subjects.
    Agabiti-Rosei E; Brown JJ; Brown WC; Fraser R; Trust PM; Lever AF; Morton JJ; Robertson JI
    Clin Endocrinol (Oxf); 1979 Mar; 10(3):227-34. PubMed ID: 455738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aldosterone regulation in essential hypertension: altered adrenal responsiveness to angiotensin II.
    Williams GH; Dluhy RG; Moore TJ
    Mayo Clin Proc; 1977 May; 52(5):312-6. PubMed ID: 870773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of prolonged and brief infusions of noradrenaline on arterial pressure and on the plasma concentrations of active renin, angiotensin II, aldosterone and potassium.
    Casals-Stenzel J; Tree M; Brown JJ; Fraser R; Lever AF; Millar JA; Morton JJ; Robertson JI; Reid JL; Hamilton C
    J Hypertens; 1983 Jun; 1(1):27-35. PubMed ID: 6397510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension.
    Shoback DM; Williams GH; Moore TJ; Dluhy RG; Podolsky S; Hollenberg NK
    J Clin Invest; 1983 Dec; 72(6):2115-24. PubMed ID: 6358261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of adrenal renin-angiotensin system in the control of aldosterone secretion in sodium-restricted rats.
    Mazzocchi G; Malendowicz LK; Markowska A; Albertin G; Nussdorfer GG
    Am J Physiol Endocrinol Metab; 2000 Jun; 278(6):E1027-30. PubMed ID: 10827004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abnormal adrenal and vascular responses to angiotensin II and an angiotensin antagonist in acromegaly.
    Moore TJ; Thein-Wai W; Dluhy RG; Dawson-Hughes BF; Hollenberg NK; Williams GH
    J Clin Endocrinol Metab; 1980 Aug; 51(2):215-22. PubMed ID: 6995474
    [No Abstract]   [Full Text] [Related]  

  • 34. Blockade of renin or angiotensin for understanding human hypertension: a comparison of propranolol, saralasin and converting enzyme blockade.
    Laragh JH; Case DB; Wallace JM; Keim H
    Fed Proc; 1977 Apr; 36(5):1781-7. PubMed ID: 191300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A specific role for saline or the sodium ion in the regulation of renin and aldosterone secretion.
    Tuck ML; Dluhy RG; Williams GH
    J Clin Invest; 1974 Apr; 53(4):988-95. PubMed ID: 4360859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aldosterone and renin-angiotensin responses to stimuli in patients with treated congestive heart failure.
    Nicholls MG; Espiner EA; Donald RA
    J Lab Clin Med; 1976 Jun; 87(6):1005-15. PubMed ID: 180213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arterial and venous angiotensin II in normal subjects. Relation to plasma renin activity and plasma aldosterone concentration, and response to posture and volume changes.
    Walker WG; Moore MA; Horvath JS; Whelton PK
    Circ Res; 1976 Jun; 38(6):477-83. PubMed ID: 773568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
    Humalda JK; Lambers Heerspink HJ; Kwakernaak AJ; Slagman MC; Waanders F; Vervloet MG; Ter Wee PM; Navis G; de Borst MH;
    Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of aldosterone secretion by the renin-angiotensin system during sodium restriction in rats.
    Aguilera G; Catt KJ
    Proc Natl Acad Sci U S A; 1978 Aug; 75(8):4057-61. PubMed ID: 211515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
    Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
    J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.